Ventana Strikes Deal to Develop CDx for Incyte's Cancer Drugs | GenomeWeb

NEW YORK (GenomeWeb News) – Roche's Ventana Medical Systems today announced a collaboration to develop companion diagnostics for Incyte's oncology drug programs.

The first test will be developed for Incyte's ID01 inhibitor program, Ventana said, adding it will support Incyte's efforts using its expertise in companion diagnostics, immunohistochemistry technology platforms, and customer support.

Financial and other terms of the deal were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.